Abstract 3166
Background
Aberrations in fibroblast growth factor receptors (FGFR) are common in multiple cancers, making them highly promising therapeutic targets. Optimal application of FGFR inhibitors requires a comprehensive understanding of the prevalence and types of FGFR mutations, which may vary significantly among ethnicities. Such analysis has not been conducted in Chinese pan-cancer. This study investigated the prevalence and the distribution of FGFR aberrations in Chinese cancer patients.
Methods
We screened genomic profiling results of plasma or tissue samples from 10,582 patients spanning 16 cancer types: lung, breast, gastric, hepatobiliary, pancreatic, soft tissue sarcoma, esophageal, ovarian, colorectal, head and neck, renal, endometrial, osteogenic sarcoma, cervical, melanoma and lymphoma.
Results
Of the 10,582 patients screened, we observed 745 patients with FGFR aberrations, revealing an overall prevalence of 7.03%. Approximately, 3.78% harbored FGFR amplification, 2.73% had other mutations and 0.53% had fusions. A majority (56.78%) of patients had FGFR1 aberrations, followed by 17.72%, 14.43% and 2.82% with FGFR3, FGFR2 and FGFR4 aberrations, respectively. Furthermore, 8.46% of patients with aberrations in more than 1 FGFR gene. The most common type of aberrations was amplification (53.69%), followed by other mutations (38.79%) and fusions (5.64%). Concurrent FGFR fusion and amplification occurred in 1.88% patients. Of the 16 cancer types, except for head and neck cancer, osteogenic sarcoma, renal carcinoma, and lymphoma, all other cancer types had FGFR aberrations detected with colorectal cancer (31.03%) having the highest prevalence. Other relatively commonly affected cancers included: gastric cancer (16.78%), breast cancer (14.27%) and esophageal cancer (12.68%). FGFR1 amplification was the most common genetic alteration in CRC, breast cancer and lung cancer. FGFR2 amplification was more commonly seen in gastric cancer. Of the patients with FGFR aberrations, 57 patients, spanning 9 cancer types, had fusions. Among them, breast cancer patients are more likely to have concurrent FGFR amplification than other cancer types (p < 0.001).
Conclusions
Our study provides a comprehensive view of FGFR aberrations in Chinese cancer patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Yang Gao.
Funding
Key Research and Development Program of Hunan province (2016JC2039).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3349 - Interplay between miR-17-5p and MALAT-1 Shapes The Cytokine Storm in Triple Negative Breast Cancer (TNBC) Tumor Microenvironment
Presenter: Raghda Soliman
Session: Poster Display session 3
Resources:
Abstract
4014 - Clinical verification on the relationship between lipid metabolism and the immune microenvironment of breast cancer
Presenter: Wataru Goto
Session: Poster Display session 3
Resources:
Abstract
4158 - The clinical and transcriptional signatures of human CD204 reveal an applicable marker for tumor associated macrophage in breast cancer
Presenter: Yunjie He
Session: Poster Display session 3
Resources:
Abstract
5392 - Activated effector T cells co-expressing multiple inhibitory receptors (IRs) are enriched in the tumor immune microenvironment in high grade serous ovarian cancer (HGSOC)
Presenter: Alice Bergamini
Session: Poster Display session 3
Resources:
Abstract
2617 - Oncolytic reovirus as a new anti-tumor strategy in castration resistant prostate cancer
Presenter: Yunlim Kim
Session: Poster Display session 3
Resources:
Abstract
2995 - Dysregulation of helper T lymphocytes in esophageal squamous cell carcinoma (ESCC) patients is highly associated with aberrant production of miR-21
Presenter: Ali Memarian
Session: Poster Display session 3
Resources:
Abstract
3597 - Myeloid derived suppressor cells but not regulatory T cells are associated with adaptive immunity and clinical outcomes in anal squamous cell carcinoma
Presenter: Christophe Borg
Session: Poster Display session 3
Resources:
Abstract
3430 - Evaluation of immune responses among responders (R) and non-responders (non-R) in a humanized mouse model with colorectal cancer (CRC) xenografts treated with combination immunotherapy
Presenter: Juan Marín Jiménez
Session: Poster Display session 3
Resources:
Abstract
1995 - ¬¬Advanced melanoma patients with high CD16+ macrophages have better response and survival to anti-PD-1 based immunotherapy
Presenter: Hansol Lee
Session: Poster Display session 3
Resources:
Abstract
3988 - Basal NK activity and early Treg function inhibition predicts Nivolumab responsiveness in metastatic renal cancer patients (REVOLUTION) trial.
Presenter: Sara Santagata
Session: Poster Display session 3
Resources:
Abstract